We then sought to determine whether adjunctive ZOL/IL-2 administrations, while expanding anti-TB Vγ2Vδ2 T effector cells and facilitating immune responses of CD4+ Th1 or CD8+ T effectors, led to immune resistance to MDR-Mtb V791 infection. Here, CD8A is linked to tuberculosis.